INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Harnessing AI and Data Analytics

Guillaume Gigon

Guillaume Gigon

Vice-President, Technology and AI

Author picture

The article “Harnessing Data Analytics and AI for Clinical Trials,” published by Applied Clinical Trials and authored by Guillaume Gigon, VP of Technology and AI at Indero, explores:

  • The transformative impact of data analytics and artificial intelligence on clinical trials.
  • The piece covers how these technologies are revolutionizing data management, enhancing operational efficiencies, and providing real-time insights that benefit both sponsors and patients.
  • Guillaume Gigon emphasizes the importance of integrating digital health tools to support evidence-based decision-making and streamline trial processes.

For a comprehensive understanding of how AI and data analytics are shaping the future of clinical research, read the full article here:
  Read More

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >